ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,465.96
-0.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) Noticias

IMNM

Immunome (IMNM)

Immunome Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMNM
FechaHoraFuenteTítuloSímboloCompañía
20/05/202407:00Business WireImmunome Announces Completion of Purchase of Assets from AtrecaNASDAQ:IMNMImmunome Inc
17/05/202416:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
17/05/202407:00Business WireImmunome Announces Promotion of Max Rosett to Chief Financial OfficerNASDAQ:IMNMImmunome Inc
14/05/202407:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
14/05/202407:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNMImmunome Inc
14/05/202407:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
14/05/202407:00Business WireImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNMImmunome Inc
08/05/202407:00Business WireImmunome to Present at 2024 Bank of America Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/05/202407:00Business WireImmunome Appoints Kinney Horn as Chief Business OfficerNASDAQ:IMNMImmunome Inc
25/04/202407:26Business WireImmunome Appoints Sandra M. Swain to Board of DirectorsNASDAQ:IMNMImmunome Inc
05/04/202407:00Business WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IMNMImmunome Inc
28/03/202415:02Business WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsNASDAQ:IMNMImmunome Inc
26/03/202407:00Business WireImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaNASDAQ:IMNMImmunome Inc
07/03/202407:00Business WireImmunome to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:IMNMImmunome Inc
01/03/202407:00Business WireImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:IMNMImmunome Inc
21/02/202420:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
20/02/202407:15Business WireImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsNASDAQ:IMNMImmunome Inc
16/02/202415:05Business WireImmunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMNMImmunome Inc
13/02/202421:38Business WireImmunome Announces Pricing of Public Offering of Common StockNASDAQ:IMNMImmunome Inc
13/02/202415:05Business WireImmunome Announces Proposed Public Offering of Common StockNASDAQ:IMNMImmunome Inc
12/02/202413:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMNMImmunome Inc
05/02/202407:00Business WireImmunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IMNMImmunome Inc
02/02/202415:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMNMImmunome Inc
08/01/202406:00Business WireImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology PlatformNASDAQ:IMNMImmunome Inc
04/01/202407:00Business WireImmunome Appoints Phil Roberts as Chief Technical OfficerNASDAQ:IMNMImmunome Inc
03/01/202407:00Business WireImmunome to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/01/202407:00Business WireImmunome Appoints Carol A. Schafer to Board of DirectorsNASDAQ:IMNMImmunome Inc
26/12/202307:30GlobeNewswire Inc.Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to ImmunomeNASDAQ:IMNMImmunome Inc
26/12/202307:30Business WireImmunome to Acquire Antibody-Related Assets and Materials from AtrecaNASDAQ:IMNMImmunome Inc
27/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNMImmunome Inc
 Showing the most relevant articles for your search:NASDAQ:IMNM

Su Consulta Reciente

USOTC
LOVV
Love (CE)
NASDAQ
PKBO
Peak Bio
NYSE
FLS
Flowserve
BIT
I06337
Banca IMI
EU
METEX
Metabolic Explo
BIT
I04640
Banca IMI
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados